Literature DB >> 27684819

Impact of alcohol consumption and body mass index on mortality from nonneoplastic liver diseases, upper aerodigestive tract cancers, and alcohol use disorders in Korean older middle-aged men: Prospective cohort study.

Sang-Wook Yi1, Jae-Seok Hong, Jee-Jeon Yi, Heechoul Ohrr.   

Abstract

Alcohol use is a leading risk factor for the global disease burden including liver diseases. However, the combined effect of alcohol use and body mass index (BMI) on alcohol-related diseases has seldom been examined. We examined whether alcohol consumption and BMI could act together to increase mortality from nonneoplastic liver diseases, upper aero-digestive tract (UADT) cancers, and alcohol use disorders (AUD) in middle-aged Korean men.107,735 men (mean age, 58.8 years) participated in a postal survey in 2004 and were followed until 2010, by linkage to national death records. Hazard ratios (HRs) of cause-specific death were calculated after adjustment for confounders.Each 5-drink (approximately 45 g alcohol) higher weekly alcohol consumption was associated with increased mortality, by approximately 70% for nonneoplastic liver disease mortality (HR = 1.70, P < 0.001), approximately 60% for UADT cancer mortality (HR = 1.64, P < 0.001), and approximately 70% for AUD mortality (HR = 1.71, P < 0.001). Generally, BMI was inversely associated with these alcohol-related diseases (HR per each 5 kg/m higher BMI = 0.18-0.46, P < 0.001 for each cause), while, in participants with BMI ≥25 kg/m, each 5 kg/m higher BMI was also associated with an elevated mortality from nonneoplastic liver diseases of approximately 150% (HR = 2.52, P = 0.001). Men with BMI < 21 kg/m and weekly alcohol consumption ≥14 drinks showed markedly higher mortality from nonneoplastic liver diseases (HR = 5.7), alcoholic liver diseases (HR = 9.3), UADT cancers (HR = 10.5), and esophageal cancer (HR = 15.5), compared to men drinking less than 1 drink/wk with BMI ≥25 kg/m. The combined effect of low BMI and high weekly alcohol consumption was 2.25- to 3.29-fold greater than the additive effect of each factor for these alcohol-related diseases (P < 0.05 for each cause).Alcohol consumption and low BMI were related to deaths from nonneoplastic liver diseases, UADT cancers, and AUD, with evidence of a supra-additive combined effect of both factors. High BMI was also related to deaths from nonneoplastic liver diseases. Men with a low BMI (<23 kg/m) are suggested to be prone to the harmful effects of alcohol.

Entities:  

Mesh:

Year:  2016        PMID: 27684819      PMCID: PMC5265912          DOI: 10.1097/MD.0000000000004876

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


Introduction

Globally, 3.3 million deaths are attributable to alcohol use every year.[ Alcohol use is considered the third leading risk factor contributing to the global disease burden in men.[ Liver diseases, which are a leading cause of death and have increased in recent years in the United Kingdom and United States,[ are closely linked with alcohol consumption, as are alcohol use disorders (AUD) and upper aerodigestive tract (UADT) cancers, such as oral cavity, larynx, and esophagus cancers. Previous research has suggested that low body mass index (BMI) is associated with liver diseases, UADT cancers, and AUD,[ while liver diseases are also associated with high BMI.[ The joint effect of alcohol consumption and BMI on these alcohol-related diseases, however, has been infrequently examined and is not well understood.[ Additionally, associations between BMI and mortality from these alcohol-related diseases per se have not been clearly established.[ A better understanding of the impact of alcohol consumption and body weight on these alcohol-related diseases may help physicians and health professionals in treating their patients and establishing strategies to reduce the burden of these diseases. We aim to evaluate whether alcohol consumption and BMI interact to increase the risk of death from these alcohol-related diseases, based on a study of middle-aged Korean men. The independent effect of each factor was also examined.

Methods

Study population

Among 187,897 men initially included in the Korean Veterans Health Study,[ 164,208 living men were identified in June 2004 after the exclusion of 23,689 individuals who were deceased or had emigrated. A postal survey was sent out on July 27, 2004, to which 117,609 men (71.6%) replied. Those with missing information on BMI (n = 3693) or alcohol consumption (n = 5743), or whose residential status was uncertain after the initial survey (n = 438) were excluded from the present study. Ultimately, 107,735 men were included in the analysis. This study was approved by the Institutional Review Board of Kwandong University. Since all able-bodied men are required to serve in the military in Korea, this study cohort is not necessarily an occupational cohort. The participants had lower overall mortality (sex–age–calendar year standardized mortality ratio [SMR] = 0.79, 95% confidence interval [CI] = 0.77–0.81) than the general Korean population.

Ascertainment of causes of death

Follow-up on deaths and their underlying causes from August 1, 2004 to December 31, 2010 was confirmed by national death records through record linkage and was complete. The International Classification of Diseases 10th Revision (ICD-10) was used to define alcohol-related causes of death, which were classified into nonneoplastic liver diseases (K70-K76), alcoholic liver disease (K70), UADT cancers (C00–C15, C30–C32), esophagus cancer (C15), and AUD (F10; mental and behavioral disorders due to use of alcohol). Liver cancer was not included in this study due to the lack of a clear dose–response relationship with alcohol consumption.

Data collection and estimation of weekly alcohol consumption

Information on smoking, alcohol consumption, physical activity, height, weight, and income was collected from the survey. BMI (kg/m2) was calculated from the self-reported weight in kilograms divided by the square of the self-reported height in meters. More details about the survey can be obtained elsewhere.[ Participants with prevalent UADT cancers diagnosed from January 1, 1992 to July 31, 2004 were assessed through the National Cancer Incidence Database.[ Participants were recorded as having prevalent nonneoplastic liver diseases, viral hepatitis (B15–B19), or substance use disorders (F10–F19) if they visited a medical institution at least once for such a condition between January 1, 2000 and July 31, 2004. Participants were asked to answer the questions “How often did you drink alcoholic beverages over this past year?” and “How many drinks of alcoholic beverages did you have on a typical drinking day?” The drinking frequency was reported as daily (estimate of drinking days per week, 7), 5–6 d/wk (5.5), 3–4 d/wk (3.5), 1–2 d/wk (1.5), 2–3 d/mo (0.58), 1 d/mo (0.23), 7–11 d/y (0.17), 4–6 d/y (0.1), 2–3 d/y (0.05), 1 d/y (0.02), none for a year (0), or never have drunk (0). Alcohol consumption (drinks) per drinking day was evaluated using an open question, with instructions that a bottle of soju (360 mL) contains 7 drinks, a can of beer (355 mL) 1.4 drinks, and so on. Weekly alcohol consumption (drinks) was estimated by multiplying the amount of alcohol consumption on a drinking day by the number of drinking days per week. Soju (a distilled alcoholic beverage native to Korea) generally contained 21% to 22% alcohol and beer 4% to 5% alcohol at the time of the survey in 2004. The amount of ethanol in a standard drink across all types of alcoholic beverages was approximately 9 g. Respondents were classified into 5 groups according to weekly alcohol consumption defined by drinks per week (<1 [reference], 1–6, 7–13, 14–27, and ≥28) and into 3 groups (<1 [reference], 1–13, and ≥14). Drinking frequency and alcohol consumption per drinking day were also classified into 5 and 3 categories, respectively. These alcohol consumption-related variables were additionally analyzed as continuous variables.

Statistical analysis

In the main analysis, no adjustment for preexisting disease status was performed in order to minimize collider-stratification bias and to increase the generalizability of our findings.[ Men with prevalent diseases were excluded in a subgroup analysis. BMI values were categorized into 7 groups (<18.5, 18.5–20.9, 21.0–22.9, 23.0–24.9, 25.0–27.4 [Reference], 27.5–29.9, ≥30 kg/m2) using cut-off points suggested by the World Health Organization,[ and into 3 groups (<21, 21–24.9, ≥25 kg/m2 [reference]).[ The reference BMI category was selected based on previous research in East Asian men that showed the lowest mortality at about 25 to 27 kg/m2.[ Cox proportional hazards models were used to calculate hazard ratios (HRs) after adjusting for the following covariates: age at enrollment (continuous variable), smoking (never, past, current smoker, or those with missing information [n = 873]), physical activity (yes, or no activity); monthly household income (<500,000, 500,000–990,000, 1,000,000–1,490,000, and ≥1,500,000 Korean won, and those with missing information [n = 4186]). In order to evaluate the combined effect of BMI and alcohol consumption, 9 combined groups of BMI and alcohol-related variables were constructed using 3 categories of both BMI and alcohol-related variables. The obese/overweight participants with the least alcohol consumption were used as the reference category. Subgroup analyses were done in which former drinkers (n = 7411; eTable 1), or men who had preexisting diseases related to each cause of death were excluded (eTable 2). In order to assess the biological interaction (departure from additivity) between BMI (low BMI vs high BMI, with a low BMI defined as <23 kg/m2) and the alcohol-related variables (high vs low-intermediate weekly alcohol consumption, with high consumption being defined as ≥14 drinks per week), the Synergy Index was calculated using previously described methodologies.[ The Synergy Index represents how many times higher the combined effect is than the additive effect of 2 factors. If no biological interaction is present, the Synergy Index is equal to 1. P-values were calculated using 2-sided tests. All statistical analyses were performed using SAS version 9.4 (SAS, Inc., Cary, NC).

Results

During 669,920 person-years of follow-up in men (mean age: 58.8 years at baseline), 338 men died from nonneoplastic liver diseases, 199 from UADT cancers, and 41 from AUD. The proportions of underweight and obesity were 2.5% and 1.2%, respectively (Table 1). The heavier drinkers tended to be somewhat younger, slightly more obese, and more likely to be current smokers, and had higher household incomes.
Table 1

Characteristics of participants according to alcohol consumption.

Characteristics of participants according to alcohol consumption. Higher levels of weekly alcohol consumption were strongly associated with increased mortality from each disease (Table 2, eTables 3 and 4). Each 5-drink increase per week was associated with 60% to 70% higher risk of mortality from nonneoplastic liver diseases, UADT cancers, and AUD. When past drinkers or people with preexisting diseases relevant to the outcomes were excluded, the HRs associated with higher alcohol consumption strengthened, rather than weakened (eTables 1 and 2).
Table 2

Death rates and adjusted∗ hazard ratios for cause-specific mortality by weekly alcohol consumption among Korean older middle-aged men.

Death rates and adjusted∗ hazard ratios for cause-specific mortality by weekly alcohol consumption among Korean older middle-aged men. BMI showed a U-curve association with nonneoplastic liver diseases (including alcoholic liver diseases), while BMI was inversely associated with mortality from other alcohol-related diseases (Fig. 1). Each 5 kg/m2 higher BMI was associated with lower mortality from nonneoplastic liver diseases (HR = 0.46, 95% CI = 0.37–0.56; eTable 5), alcoholic liver disease (HR = 0.40, 95% CI = 0.30–0.53), UADT cancers (HR = 0.32, 95% CI = 0.24–0.42), esophagus cancer (HR = 0.36, 95% CI = 0.25–0.52), and AUD (HR = 0.18, 95% CI = 0.10–0.33). When restricted to BMI ≥25 kg/m2, each 5 kg/m2 higher BMI was associated with higher mortality from nonneoplastic liver diseases (HR = 2.52, 95% CI = 1.49–4.26) and alcoholic liver disease (HR = 2.13, 95% CI = 0.80–5.66). When men with preexisting diseases relevant to the outcomes were excluded, the general inverse associations remained relatively unchanged, whereas higher mortality rates from nonneoplastic liver diseases, including alcoholic liver disease, showed weakened associations with high BMI (eFigure 1, eTable 6).
Figure 1

Hazard ratios of cause-specific mortality according to body mass index (BMI). Hazard ratios were calculated using Cox proportional hazard models. Seven BMI categories (<18.5, 18.5–20.9, 21–22.9, 23–24.9, 25–27.4 [reference], 27.5–27.9, and ≥30 kg/m2) were used. The mean value was used as a representative value of each BMI category. The analyses were adjusted for age, cigarette smoking, physical activity, household income, and weekly alcohol consumption (5 groups). For esophageal cancer and alcohol use disorders, no deaths were observed in the BMI ≥ 30 categories. UADT = upper aerodigestive tract.

Hazard ratios of cause-specific mortality according to body mass index (BMI). Hazard ratios were calculated using Cox proportional hazard models. Seven BMI categories (<18.5, 18.5–20.9, 21–22.9, 23–24.9, 25–27.4 [reference], 27.5–27.9, and ≥30 kg/m2) were used. The mean value was used as a representative value of each BMI category. The analyses were adjusted for age, cigarette smoking, physical activity, household income, and weekly alcohol consumption (5 groups). For esophageal cancer and alcohol use disorders, no deaths were observed in the BMI ≥ 30 categories. UADT = upper aerodigestive tract. In the stratified analyses using 3 BMI groups, the highest alcohol consumption group showed a strong positive association with mortality from alcohol-related diseases among men with BMIs of 12 to 20.9 and 21 to 24.9 kg/m2, while the associations were generally weak in overweight/obese men (eTable 7). In the analyses using 9 groups combining BMI and alcohol-related variables, higher alcohol consumption was associated with a higher risk of death from alcohol-related diseases, as BMI decreased (Fig. 2, eFigures 2–4).
Figure 2

Hazard ratios of cause-specific mortality according to 9 groups combining body mass index (BMI) and weekly alcohol consumption. Hazard ratios were calculated using Cox proportional hazard models after adjusting for age, cigarette smoking, physical activity, and household income. Persons with a BMI ≥ 25 kg/m2 and weekly alcohol consumption of less than 1 drink were the reference group. One drink was defined as containing approximately 9 g of ethanol. For alcohol use disorders, persons with a BMI ≥25 kg/m2 and weekly alcohol consumption of 0 to 13 drinks (<1 or 1–13 drinks/wk) were the reference group, due to the absence of deaths in persons with a BMI ≥ 25 kg/m2 and an alcohol consumption of less than 1 drink/wk.

Hazard ratios of cause-specific mortality according to 9 groups combining body mass index (BMI) and weekly alcohol consumption. Hazard ratios were calculated using Cox proportional hazard models after adjusting for age, cigarette smoking, physical activity, and household income. Persons with a BMI ≥ 25 kg/m2 and weekly alcohol consumption of less than 1 drink were the reference group. One drink was defined as containing approximately 9 g of ethanol. For alcohol use disorders, persons with a BMI ≥25 kg/m2 and weekly alcohol consumption of 0 to 13 drinks (<1 or 1–13 drinks/wk) were the reference group, due to the absence of deaths in persons with a BMI ≥ 25 kg/m2 and an alcohol consumption of less than 1 drink/wk. Meanwhile, in persons with low alcohol consumption (less than 1 drink per week), BMI < 21 was not associated with higher mortality from nonneoplastic liver diseases (including alcoholic liver disease) compared with BMI ≥25 (Fig. 2), or compared with BMI 25 to 27.4 in men without prevalent nonneoplastic liver diseases (Fig. 3).
Figure 3

Hazard ratios of mortality from nonneoplastic liver diseases according to 12 groups combining body mass index (BMI) and weekly alcohol consumption in persons with or without viral hepatitis and nonneoplastic liver diseases at baseline. Hazard ratios were calculated using Cox proportional hazard models after adjusting for age, cigarette smoking, physical activity, and household income. Persons with a BMI 25 to 27.4 kg/m2 and weekly alcohol consumption of less than 1 drink were the reference group. One drink was defined as containing approximately 9 g of ethanol. Participants were recorded as having prevalent nonneoplastic liver diseases (K70–K76) or viral hepatitis (B15–B19) at baseline if they visited a medical institution at least once for a given condition between January 1, 2000 and July 31, 2004.

Hazard ratios of mortality from nonneoplastic liver diseases according to 12 groups combining body mass index (BMI) and weekly alcohol consumption in persons with or without viral hepatitis and nonneoplastic liver diseases at baseline. Hazard ratios were calculated using Cox proportional hazard models after adjusting for age, cigarette smoking, physical activity, and household income. Persons with a BMI 25 to 27.4 kg/m2 and weekly alcohol consumption of less than 1 drink were the reference group. One drink was defined as containing approximately 9 g of ethanol. Participants were recorded as having prevalent nonneoplastic liver diseases (K70–K76) or viral hepatitis (B15–B19) at baseline if they visited a medical institution at least once for a given condition between January 1, 2000 and July 31, 2004. In the 4-group analysis used to evaluate the biological interaction between BMI and alcohol consumption, the Synergy Index indicated that the combined effect of low BMI and high weekly alcohol consumption on mortality from these alcohol-related diseases was 2.25- to 3.29-fold greater than the additive effect of each factor (Fig. 4; P < 0.05 for each cause).
Figure 4

Hazard ratios (HRs) of the contributions of alcohol consumption and low body mass index (BMI) to cause-specific mortality. Alcohol consumption was classified into 2 groups (≥14 vs 0–13 drinks/wk), while BMI was classified into 2 groups (<23 vs ≥23 kg/m2). The HRs were calculated using Cox proportional hazard models after adjusting for age, cigarette smoking, physical activity, and household income. Persons with a BMI ≥ 23 kg/m2 and a weekly alcohol consumption of 0 to 13 drinks were the reference group. The Synergy Index represents how many times higher the combined effect (interaction) was than the additive effect of alcohol consumption and low BMI, with a value of 1 indicating no biological interaction. CI = confidence interval.

Hazard ratios (HRs) of the contributions of alcohol consumption and low body mass index (BMI) to cause-specific mortality. Alcohol consumption was classified into 2 groups (≥14 vs 0–13 drinks/wk), while BMI was classified into 2 groups (<23 vs ≥23 kg/m2). The HRs were calculated using Cox proportional hazard models after adjusting for age, cigarette smoking, physical activity, and household income. Persons with a BMI ≥ 23 kg/m2 and a weekly alcohol consumption of 0 to 13 drinks were the reference group. The Synergy Index represents how many times higher the combined effect (interaction) was than the additive effect of alcohol consumption and low BMI, with a value of 1 indicating no biological interaction. CI = confidence interval.

Discussion

In this large prospective cohort study, alcohol intake displayed a strong linear association with mortality from nonneoplastic liver diseases, UADT cancers (including esophagus cancer), and AUD. Each 5-drink (approximately 45 g alcohol) increase in weekly alcohol consumption was associated with increased mortality, by approximately 60% to 70% for mortality from nonneoplastic liver diseases, UADT cancers, and AUD. Low BMI was generally associated with higher mortality from these alcohol-related diseases, while high BMI was also strongly associated with higher mortality from nonneoplastic liver diseases. Among participants with BMI ≥ 25 kg/m2, each 5 kg/m2 increment in BMI increased mortality from nonneoplastic liver diseases by approximately 150%. The combined effect of low BMI and high alcohol consumption was substantially greater than the additive effect of each factor analyzed independently.

Association between BMand alcohol-related diseases

Both low and high BMI were associated with increased mortality from liver diseases, in accordance with 2 large cohort studies.[ The magnitude of relative risk estimates seemed to be greater both for low and high BMIs in the present study than in previous research.[ Regarding UADT cancers, the observed inverse associations between BMI and UADT cancers (including esophagus cancer, mostly squamous cell carcinoma[) concur with the majority of, but not all,[ previous studies.[ The associations of body weight with alcohol consumption and AUD remain controversial.[ Associations between BMI and mortality from AUD have infrequently been evaluated. Our study found a strong inverse relationship.

Combined effects of BMand alcohol consumption on alcohol-related mortality

Two prospective studies have examined the combined effect of BMI and alcohol consumption on liver diseases.[ A study in UK men found a supra-additive interaction between high BMI and alcohol consumption. In the Million Women Study in the United Kingdom, obesity contributed independently to the mortality rate of liver cirrhosis, but not to the relative risk. When we further classified the overweight range into 25 to 27.4 and ≥27.5 kg/m2 to evaluate the combined effect of high BMI and alcohol consumption, we found no evidence of supra-additive interaction (eFigure 5). Regarding UADT cancers, several case–control studies have suggested that low BMIs may enhance the effects of alcohol consumption on the risk of oral cavity and oropharyngeal cancer[; however, prospective studies have not confirmed this joint effect.[ Few studies have examined the joint effect on esophagus cancer or AUD. Our analysis clearly showed that low BMI and high alcohol consumption independently increased the mortality from alcohol-related diseases, with a supra-additive combined effect for each disease. However, low BMI may be more an effect modifier of alcohol consumption than an independent risk factor for nonneoplastic liver diseases, since, in persons with low weekly alcohol consumption (less than 1 drink), low BMI was not associated with higher mortality (Fig. 2), especially in persons without prevalent liver diseases (Fig. 3).

Potential mechanisms

Large cohort studies have found low BMIs (e.g., below 22.5) to be associated with higher liver diseases mortality.[ In a general Scottish population, BMI was inversely associated with hospitalization due to alcohol-related harm, including alcoholic liver disease and liver cirrhosis.[ Several case–control studies found a synergic effect of low BMI on the association between alcohol consumption and UADT cancers.[ These studies, however, provided no clear explanation. Increased alcohol-related mortality associated with low BMI, as well as a supra-additive combined effect of low BMI and higher alcohol consumption, may be partly explained by higher alcohol consumption relative to body weight in persons with lower BMI than with higher BMI. The overweight/obese men consumed the least amount relative to their body weight (0.14 drinks/wk/kg body weight in men with BMI ≥ 25 kg/m2; 0.18 drinks/wk/kg body weight in men with BMI < 21 kg/m2; P < 0.001) in the present study in accordance with previous findings that higher BMI was associated with lower blood alcohol concentrations.[ Therefore, the harmful effects of alcohol may be greater in persons with lower BMIs than with higher BMIs. For nonneoplastic liver diseases, sarcopenia (the decline of muscle mass and strength) may partially explain the observed associations. Sarcopenia may be associated with liver fibrosis,[ and it becomes more prevalent as BMI decreases.[ Thus, a potential synergic interaction between sarcopenia and alcohol consumption may increase the mortality rate in persons with a lower BMI. Regarding higher liver disease mortality in persons with BMI ≥ 27.5, mechanisms such as the crosstalk between dysfunctional and insulin-resistant adipocytes and the liver may promote the development of fatty liver disease, which may subsequently lead to liver cirrhosis, a fatal liver disease.[ Additionally, genetic traits, such as those linked to the alcohol dehydrogenase 1B (ADH1B) gene,[ which is related both to alcohol metabolism and BMI, might have played a role in the observed findings.

Implications

Our study clearly showed that, even if lower BMI per se is not a risk factor, the harmful effect of alcohol consumption on these alcohol-related diseases was substantially greater in persons with a lower BMI. Persons with low-normal weight (18.5–22.9 kg/m2), should be recognized as prone to the harmful effects of alcohol—if not for all alcohol-related diseases, then at least for nonneoplastic liver diseases, UADT cancers, and AUD. In obese persons, weight reduction may substantially lower the burden of nonneoplastic liver diseases.

Strengths and limitations

The prospective design of this study is a clear strength. Due to the large number of events, we were able to reliably evaluate the effect of alcohol consumption and BMI. Follow-up was complete, meaning that no bias was present due to loss to follow-up. Since preexisting diseases were identified using the nationwide database, bias related to self-reported information regarding preexisting conditions was minimized, while conditions important for assessing specific causes of mortality were controlled for in the analyses (e.g., viral hepatitis infection for nonneoplastic liver diseases). This study also has several limitations. BMI was calculated based on self-reported height and weight. Alcohol consumption was assessed using a self-reported questionnaire. However, self-reported measures of alcohol intake are known to be reasonably valid and reliable.[ BMI and alcohol consumption may have changed over the follow-up period. Since the Korean sample was slim overall, this study had a limited ability to detect associations in the obese range. Generalizability may be a limitation, since the participants were Koreans and had Vietnam War experience. Our study participants had a lower mortality than the general male population of Korea (SMR = 0.79), while Koreans have a life expectancy comparable to those of other Organization for Economic Co-operation and Development (OECD) populations. Since the associations of BMI with mortality may differ by ethnicity, region, sex, and age,[ some of our findings may need to be confirmed in other populations. However, the effects of alcohol consumption and BMI were generally consistent for several alcohol-related diseases over several alcohol consumption measures in various subgroup and sensitivity analyses. This aspect of our main findings may make them more generalizable to other populations.

Conclusions

This large prospective cohort study in Korean men found that higher alcohol consumption was strongly associated with increased mortality from nonneoplastic liver diseases, UADT cancers, and AUD. High BMI (≥27.5 kg/m2) was strongly associated with higher mortality from nonneoplastic liver diseases, while low BMI was strongly associated with higher mortality from nonneoplastic liver diseases, UADT cancers, and AUD. The harmful effects of alcohol consumption on mortality from these alcohol-related diseases were generally greater as BMI decreased. The combined effect of low BMI and high alcohol consumption was greater than the independent additive effects of these 2 factors. For nonneoplastic liver diseases, low BMI may be more of an effect modifier of alcohol consumption than a risk factor per se.

Acknowledgment

The authors sincerely thank the staff of the Korean National Statistical Office for providing the mortality data used herein.
  30 in total

Review 1.  The validity of self-reports of alcohol consumption: state of the science and challenges for research.

Authors:  Frances K Del Boca; Jack Darkes
Journal:  Addiction       Date:  2003-12       Impact factor: 6.526

2.  Epidemiology of hospitalization due to alcohol-related harm: evidence from a Scottish cohort study.

Authors:  R Lawder; I Grant; C Storey; D Walsh; B Whyte; P Hanlon
Journal:  Public Health       Date:  2011-07-26       Impact factor: 2.427

Review 3.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.

Authors:  Kenneth Cusi
Journal:  Gastroenterology       Date:  2012-02-08       Impact factor: 22.682

4.  Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study.

Authors:  George N Ioannou; Noel S Weiss; Kris V Kowdley; Jason A Dominitz
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

5.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Stephen S Lim; Theo Vos; Abraham D Flaxman; Goodarz Danaei; Kenji Shibuya; Heather Adair-Rohani; Markus Amann; H Ross Anderson; Kathryn G Andrews; Martin Aryee; Charles Atkinson; Loraine J Bacchus; Adil N Bahalim; Kalpana Balakrishnan; John Balmes; Suzanne Barker-Collo; Amanda Baxter; Michelle L Bell; Jed D Blore; Fiona Blyth; Carissa Bonner; Guilherme Borges; Rupert Bourne; Michel Boussinesq; Michael Brauer; Peter Brooks; Nigel G Bruce; Bert Brunekreef; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Fiona Bull; Richard T Burnett; Tim E Byers; Bianca Calabria; Jonathan Carapetis; Emily Carnahan; Zoe Chafe; Fiona Charlson; Honglei Chen; Jian Shen Chen; Andrew Tai-Ann Cheng; Jennifer Christine Child; Aaron Cohen; K Ellicott Colson; Benjamin C Cowie; Sarah Darby; Susan Darling; Adrian Davis; Louisa Degenhardt; Frank Dentener; Don C Des Jarlais; Karen Devries; Mukesh Dherani; Eric L Ding; E Ray Dorsey; Tim Driscoll; Karen Edmond; Suad Eltahir Ali; Rebecca E Engell; Patricia J Erwin; Saman Fahimi; Gail Falder; Farshad Farzadfar; Alize Ferrari; Mariel M Finucane; Seth Flaxman; Francis Gerry R Fowkes; Greg Freedman; Michael K Freeman; Emmanuela Gakidou; Santu Ghosh; Edward Giovannucci; Gerhard Gmel; Kathryn Graham; Rebecca Grainger; Bridget Grant; David Gunnell; Hialy R Gutierrez; Wayne Hall; Hans W Hoek; Anthony Hogan; H Dean Hosgood; Damian Hoy; Howard Hu; Bryan J Hubbell; Sally J Hutchings; Sydney E Ibeanusi; Gemma L Jacklyn; Rashmi Jasrasaria; Jost B Jonas; Haidong Kan; John A Kanis; Nicholas Kassebaum; Norito Kawakami; Young-Ho Khang; Shahab Khatibzadeh; Jon-Paul Khoo; Cindy Kok; Francine Laden; Ratilal Lalloo; Qing Lan; Tim Lathlean; Janet L Leasher; James Leigh; Yang Li; John Kent Lin; Steven E Lipshultz; Stephanie London; Rafael Lozano; Yuan Lu; Joelle Mak; Reza Malekzadeh; Leslie Mallinger; Wagner Marcenes; Lyn March; Robin Marks; Randall Martin; Paul McGale; John McGrath; Sumi Mehta; George A Mensah; Tony R Merriman; Renata Micha; Catherine Michaud; Vinod Mishra; Khayriyyah Mohd Hanafiah; Ali A Mokdad; Lidia Morawska; Dariush Mozaffarian; Tasha Murphy; Mohsen Naghavi; Bruce Neal; Paul K Nelson; Joan Miquel Nolla; Rosana Norman; Casey Olives; Saad B Omer; Jessica Orchard; Richard Osborne; Bart Ostro; Andrew Page; Kiran D Pandey; Charles D H Parry; Erin Passmore; Jayadeep Patra; Neil Pearce; Pamela M Pelizzari; Max Petzold; Michael R Phillips; Dan Pope; C Arden Pope; John Powles; Mayuree Rao; Homie Razavi; Eva A Rehfuess; Jürgen T Rehm; Beate Ritz; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Jose A Rodriguez-Portales; Isabelle Romieu; Robin Room; Lisa C Rosenfeld; Ananya Roy; Lesley Rushton; Joshua A Salomon; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; Amir Sapkota; Soraya Seedat; Peilin Shi; Kevin Shield; Rupak Shivakoti; Gitanjali M Singh; David A Sleet; Emma Smith; Kirk R Smith; Nicolas J C Stapelberg; Kyle Steenland; Heidi Stöckl; Lars Jacob Stovner; Kurt Straif; Lahn Straney; George D Thurston; Jimmy H Tran; Rita Van Dingenen; Aaron van Donkelaar; J Lennert Veerman; Lakshmi Vijayakumar; Robert Weintraub; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Warwick Williams; Nicholas Wilson; Anthony D Woolf; Paul Yip; Jan M Zielinski; Alan D Lopez; Christopher J L Murray; Majid Ezzati; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

6.  Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies.

Authors:  Carole L Hart; David S Morrison; G David Batty; Richard J Mitchell; George Davey Smith
Journal:  BMJ       Date:  2010-03-11

7.  Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study.

Authors:  Bette Liu; Angela Balkwill; Gillian Reeves; Valerie Beral
Journal:  BMJ       Date:  2010-03-11

8.  Esophageal cancer and body mass index: results from a prospective study of 220,000 men in China and a meta-analysis of published studies.

Authors:  Margaret Smith; Maigeng Zhou; Gary Whitlock; Gonghuan Yang; Alison Offer; Gei Hui; Richard Peto; Zhengjing Huang; Zhengming Chen
Journal:  Int J Cancer       Date:  2008-04-01       Impact factor: 7.396

9.  Lifetime body mass index and risk of oral cavity and oropharyngeal cancer by smoking and drinking habits.

Authors:  A Nieto; M J Sánchez; C Martínez; X Castellsagué; M J Quintana; X Bosch; M Conde; N Muñoz; R Herrero; S Franceschi
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

10.  Body mass index and risk of subtypes of head-neck cancer: the Netherlands Cohort Study.

Authors:  Denise H E Maasland; Piet A van den Brandt; Bernd Kremer; Leo J Schouten
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379

View more
  9 in total

1.  A longitudinal evaluation of alcohol intake throughout adulthood and colorectal cancer risk.

Authors:  Ana-Lucia Mayén; Vivian Viallon; Edoardo Botteri; Cecile Proust-Lima; Vincenzo Bagnardi; Veronica Batista; Amanda J Cross; Nasser Laouali; Conor J MacDonald; Gianluca Severi; Verena Katzke; Manuela M Bergmann; Mattias B Schulze; Anne Tjønneland; Anne Kirstine Eriksen; Christina C Dahm; Christian S Antoniussen; Paula Jakszyn; Maria-Jose Sánchez; Pilar Amiano; Sandra M Colorado-Yohar; Eva Ardanaz; Ruth Travis; Domenico Palli; Sieri Sabina; Rosario Tumino; Fulvio Ricceri; Salvatore Panico; Bas Bueno-de-Mesquita; Jeroen W G Derksen; Emily Sonestedt; Anna Winkvist; Sophia Harlid; Tonje Braaten; Inger Torhild Gram; Marko Lukic; Mazda Jenab; Elio Riboli; Heinz Freisling; Elisabete Weiderpass; Marc J Gunter; Pietro Ferrari
Journal:  Eur J Epidemiol       Date:  2022-09-05       Impact factor: 12.434

2.  Relationships between serum iron and liver diseases in nutrition intervention trials: A nested case-control study.

Authors:  Yiwei Liu; Jian Yin; Sanford M Dawsey; Bin Liu; Neal D Freedman; Jianfeng Cui; Philip R Taylor; Liangyu Yin; Christian C Abnet; Jinhu Fan; Wen Chen; Li Zhong; Youlin Qiao
Journal:  Cancer Epidemiol       Date:  2022-04-11       Impact factor: 2.890

Review 3.  Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting.

Authors:  Matias A Avila; Jean-François Dufour; Alexander L Gerbes; Fabien Zoulim; Ramon Bataller; Patrizia Burra; Helena Cortez-Pinto; Bin Gao; Ian Gilmore; Philippe Mathurin; Christophe Moreno; Vladimir Poznyak; Bernd Schnabl; Gyongyi Szabo; Maja Thiele; Mark R Thursz
Journal:  Gut       Date:  2019-12-26       Impact factor: 23.059

4.  Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Authors:  Paul M Trembling; Sophia Apostolidou; Aleksandra Gentry-Maharaj; Julie Parkes; Andy Ryan; Sudeep Tanwar; Matthew Burnell; Ian Jacobs; Usha Menon; William M Rosenberg
Journal:  BMC Public Health       Date:  2017-06-28       Impact factor: 3.295

Review 5.  An update of the WCRF/AICR systematic literature review and meta-analysis on dietary and anthropometric factors and esophageal cancer risk.

Authors:  S Vingeliene; D S M Chan; A R Vieira; E Polemiti; C Stevens; L Abar; D Navarro Rosenblatt; D C Greenwood; T Norat
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

6.  Obesity and the risk of primary liver cancer: A systematic review and meta-analysis.

Authors:  Won Sohn; Hyun Woong Lee; Sangheun Lee; Jin Hong Lim; Min Woo Lee; Chan Hyuk Park; Seung Kew Yoon
Journal:  Clin Mol Hepatol       Date:  2020-11-26

7.  Alcohol drinking and risks of liver cancer and non-neoplastic chronic liver diseases in China: a 10-year prospective study of 0.5 million adults.

Authors:  Pek Kei Im; Iona Y Millwood; Christiana Kartsonaki; Yu Guo; Yiping Chen; Iain Turnbull; Canqing Yu; Huaidong Du; Pei Pei; Jun Lv; Robin G Walters; Liming Li; Ling Yang; Zhengming Chen
Journal:  BMC Med       Date:  2021-09-17       Impact factor: 8.775

8.  Impact of body mass and alcohol consumption on all-cause and liver mortality in 240 000 adults in the United States.

Authors:  Jayadeep Patra; Charlotte Buckley; William C Kerr; Alan Brennan; Robin C Purshouse; Jürgen Rehm
Journal:  Drug Alcohol Rev       Date:  2021-03-08

Review 9.  The role of alcohol use in the aetiology and progression of liver disease: A narrative review and a quantification.

Authors:  Jürgen Rehm; Jayadeep Patra; Alan Brennan; Charlotte Buckley; Thomas K Greenfield; William C Kerr; Jakob Manthey; Robin C Purshouse; Pol Rovira; Paul A Shuper; Kevin D Shield
Journal:  Drug Alcohol Rev       Date:  2021-03-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.